December 22, 2022
Medicines Development for Global Health receives US$4.9M grant for moxidectin programs
Medicines Development for Global Health recently received a US$4.9M grant from the Bill & Melinda Gates Foundation to generate additional clinical and field implementation data on moxidectin for the treatment of onchocerciasis and lymphatic filariasis. The 4-year funding will help Medicines Development for Global Health to conclude two key studies: a repeat-dose trial comparing annual or biannual doses of either moxidectin or ivermectin and a single-dose endemic community safety study of moxidectin and implement pilot field projects. Medicines Development for Global Health greatly values the technical and financial support from the Bill & Melinda Gates Foundation to progress moxidectin as a tool for accelerating elimination of these diseases.
Sally Kinrade, Vice President, and Project Leader for Onchocerciasis and Lymphatic Filariasis noted, “Medicines Development for Global Health is working to generate data required to support inclusion of moxidectin in World Health Organization treatment guidelines and its use in community-directed treatment programs in endemic areas. The generosity of the Bill & Melinda Gates Foundation grant is instrumental in enabling the introduction of moxidectin.”
For more information about this grant, visit the Foundation's website.